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Efficient production of eukaryotic expression vectors requires the selection of plasmid-
containing bacteria. To avoid the risk of dissemination of antibiotic resistance markers, we 
developed a new system to produce a family of plasmids Free of Antibiotic Resistance genes, 
called pFARs. The strategy is based on the suppression of a chromosomal nonsense mutation 
by a plasmid-borne function. The amber mutation was introduced into the Escherichia coli 
thyA gene that encodes a thymidylate synthase required for dTMP synthesis, resulting in 
thymidine auxotrophy. In parallel, a small plasmid vector that carries an amber suppressor t-
RNA gene was entirely synthesised. The introduction of pFAR plasmids into an optimised 
thyA mutant restored normal growth to the auxotrophic strain, and led to an efficient 
production of monomeric supercoiled plasmids, as required for clinical trials. Luciferase 
activities measured after intramuscular injection and electrotransfer of LUC-encoding pFAR 
vector were similar to those obtained with a commercial vector containing the same 
expression cassette. Interestingly, whereas luciferase activities decreased within three weeks 
after intradermal electrotransfer of conventional expression vectors, sustained levels were 
observed with the pFAR derivative. Thus, pFAR plasmids represent a novel family of biosafe 
eukaryotic expression vectors, suitable for gene therapy.  
 




High expression levels of therapeutic proteins in transfected mammalian cells require an 
optimal intracellular gene delivery. Although viral vectors are considered to be efficient 
vehicles for gene transfer, their use is restricted by several major limiting factors, such as the 
occurrence of immune responses to viral components, possible insertional mutagenesis into 
host genome and high production costs.1-4 These drawbacks can be avoided by using easily 
produced non-viral expression vectors that remain in episomal state inside eukaryotic cells.5,6 
Furthermore, the development of physical methods (e.g: hydrodynamic delivery or 
electrotranfer) used to administer plasmids in vivo, allowed a significant increase in protein 
expression levels7,8 and reconsidering non-viral expression vectors as therapeutic gene 
vehicles. 
Non-viral expression vectors consist of three main classes: plasmidic DNA, MIDGE vectors,9 
and minicircles.10-12 The two last ones are produced from a parental plasmid, which contains a 
eukaryotic expression cassette flanked by either restriction enzyme- or recombinase-
recognized specific sequences, respectively. After plasmid propagation, the expression 
cassette is released by either enzymatic digestion or intramolecular recombination and further 
purified.9-12 MIDGE vectors and minicircles present the main advantage of being totally free 
of bacterial sequences that seem to promote heterochromatin formation, leading to gene 
silencing in certain organs such as liver.13 In muscles, however, prokaryotic sequences do not 
appear to impair prolonged gene expression,5 thus making dispensable laborious preparations 
of MIDGE or minicircle vectors. The third group of non-viral vectors is represented by 
plasmidic DNA that are produced from dividing bacterial cells grown in the presence of 
antibiotics to ensure plasmid maintenance and propagation. Although plasmids encoding 
proteins that inactivate antibiotics of the aminoside class (such as kanamycin which is not 
normally used in human health) have been approved for some clinical applications, several 
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alternatives have been envisioned to avoid them for safety concerns. All strategies are based 
on the same following principle: growth of bacterial conditional mutants relies upon the 
presence of plasmids. Plasmidic expression vectors can harbour either (i) several copies of the 
lacZ operator sequences that titrate a repressor bound to an essential chromosomal gene 
promoter/operator region14,15 (ii) a suppressor t-RNA coding sequence enabling complete 
traduction of a protein playing a role in the arginin biosynthetic pathway16,17 (iii) a replication 
origin encoding an RNA molecule involved in the regulation of an essential E. coli gene via 
an RNA/RNA interference mechanism.18,19 
In this paper, we describe a novel combination E. coli producer strain / plasmids Free of 
Antibiotic Resistance markers, referred as pFARs. On one side, a nonsense mutation (CAT → 
TAG) was introduced into the essential E. coli thyA gene that encodes a thymidylate synthase, 
an enzyme required for DNA precursor synthesis. The thyA mutant was further optimised for 
the production of a family of new and small pFAR vectors that encode an amber suppressor t-
RNA. Finally, pFAR efficiency as eukaryotic expression vectors was assessed using the 
luciferase reporter gene expressed from the cytomegalovirus (CMV) promoter, after plasmid 
injection into muscle and skin, followed by electrotransfer. This physical method consists of 
applying electric field-mediated intracellular delivery via a mechanism mostly composed of 
cell permeabilisation and DNA uptake through electrophoresis, allowing an increase in 
protein expression level by a two-log factor in both organs.8,20-22 
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Results 
Description of a novel combination of an E. coli producer strain / plasmids devoid of 
Antibiotic Resistance Markers 
To propagate plasmids free of antibiotic resistance markers, a nonsense mutation (TAG) was 
introduced into the E. coli thyA gene that encodes a thymidylate synthase (EC 2.1.1.45). This 
enzyme is required for de novo synthesis of thymidine monophosphate (dTMP) from 
deoxyuridine monophosphate (dUMP). Mutation in thyA leads to thymidine auxotrophy23 that 
can be overcome by adding exogenous thymidine in the growth medium. The supplement 
penetrates into bacterial cells, via a nucleoside transporter, and is transformed into dTMP by a 
thimidine kinase (EC 27.1.75). In the absence of thymidine, only the strains that contain a 
plasmid encoding a suppressor t-RNA enabling full traduction of ThyA can grow (Fig. 1).  
An amber mutation, which substitutes the CAT encoding His147 to TAG, was introduced into 
the cloned thyA region and subsequently inserted into the non-pathogenic E. coli strain 
MG1655 genome by homologous recombination. The selected mutant did not grow on 
minimal medium unless thymidine was added. To facilitate cloning procedures and plasmid 
preparations for routine laboratory assays, we identified another selective complex medium: 
the Mueller Hinton (MH) broth known to contain only traces of thymidine24 and in which the 
thyA mutant did not grow.  
In parallel, a plasmid devoid of antibiotic resistance markers was constructed. First, the 
histidine suppressor t-RNA gene was introduced into pVAX2, an expression vector that 
carries a kanamycin resistance gene.25 The suppressor t-RNA gene is an allelic form of hisR, 
which codes a histidine t-RNA with a modified anticodon (AUG → CUA) followed by two 
AA to yield 5’CUAAA. This additional modification was shown to improve the suppression 
efficiency of the nonsense mutation.26 Expression of the t-RNA suppressor is under the 
control of the E. coli lipoprotein promoter region (lpp) and the transcription terminator 
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sequence from the rrnC operon,27 two cis-regulatory elements only active in prokaryotic cells. 
The kanamycin resistance gene was subsequently deleted from pVAX2.sup.t-RNA and the 
resulting plasmid, Free of Antibiotic Resistance marker, was called pFAR1. To validate the 
proposed strategy, pFAR1 was introduced into the thyA mutant by transformation. Whereas 
no bacteria electroporated with water appeared on selective medium (MH), pFAR-
transformed cells grew well even in the absence of thymidine, indicating that the suppression 
of the nonsense mutation could sustain bacterial growth. Plasmid DNA were prepared from 
several transformants grown overnight in selective medium. They all appeared to contain 
pFAR1, with the expected size and restriction profiles. All these data showed that this novel 
combination of E. coli thyA mutant / pFAR plasmid can be used to produce plasmids devoid 
of antibiotic resistance markers and was therefore further optimised.  
 
Optimisation of the bacterial producer strain and of the expression eukaryotic vector 
The use of plasmid DNA for clinical trials requires that they meet some defined criteria such 
as purity and topology.28,29 As most laboratory strains contain suppressor t-RNA genes, the 
amber mutation had to be introduced into the wild-type reference strain MG1655. To reach 
optimal conditions for plasmid production, the thyA mutant needed therefore to be further 
optimised. DNA quality produced by bacterial strains can be improved by mutating the endA 
gene that encodes the endonuclease 1. Although the function of this enzyme is not fully 
understood, the quality of plasmid DNA purified from endA+ strains appears inconsistent, 
degrading upon long-term storage.30 To overcome this, an internal region of endA (coding 
amino acids 7-234 of the 234 AA-long EndA protein) was deleted from the thyA mutant 
chromosome, to give a double thyA endA mutant.  
During plasmid propagation and replication, intermolecular recombination between 
homologous sequences can occur, leading to multimers formation and increase in plasmid 
 7
size. Plasmid copy number being controlled by the replication origin concentration, 
recombination events will have an influence on the monomers/multimers ratio, resulting in 
inconsistency from one plasmid batch to another, which is not suitable for pharmaceutical 
applications.28,29 To avoid multimers formation, the internal region of recA that encodes a 
recombinase (353 amino-acids) was deleted (AA: 5-343) from the double thyA endA mutant 
genome. As shown Figure 2a, plasmids prepared from the triple mutant predominantly formed 
monomeric closed circular DNA whereas those purified from the simple thyA mutant also 
appeared as dimers or multimers.  
Having optimised the bacterial producer strain, our next objective was to further develop the 
plasmid vector. To minimize bacterial sequences and plasmid size, a new DNA vector was 
entirely synthesised and called pFAR4 (Fig. 3). pFAR4 has a small size (1.1-kb), it contains a 
pUC-type origin of replication, the same histidine suppressor t-RNA gene as pFAR1 and a 
multiple cloning site to allow easy cloning procedures. When introduced into the triple thyA 
endA recA mutant, pFAR4 showed the same properties as pFAR1 such as the ability to restore 
normal growth to the thymidine auxotrophic strain. In selective MH medium, the growth 
curve of the optimised thyA mutant containing a pFAR4 derivative was similar to that of the 
strain DH5α harbouring pVAX2-LUC propagated in the presence of kanamycin (Fig. 2b). 
Furthermore, at a similar optical density (OD600~0.9) or after overnight growth, the amount 
of pFAR4 plasmids purified from the triple thyA endA recA mutant was equivalent to that of a 
pVAX2 derivative prepared from DH5α grown in LB medium supplemented with kanamycin 
(Fig. 2c). Thus, bacterial and plasmid optimisation led to the production of plasmids devoid of 
antibiotic resistance markers with a good yield and appropriate criteria for in vivo studies.  
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Assessment of pFAR plasmids as eukaryotic expression vectors 
To assess whether pFAR plasmids could be used for in vivo studies, the cytoplasmic firefly 
luciferase-encoding gene was cloned into pFAR1 and pFAR4 (Fig. 3). The reporter gene is 
under the control of the ubiquitous cytomegalovirus (CMV) promoter and the bovine growth 
hormone (BGH) polyadenylation signal. Plasmids pVAX2-LUC, pFAR1-LUC and pFAR4-
CMV LUC BGH, which contain the same expression cassette, were injected into mouse tibial 
cranial muscles and subsequently electrotransferred. Luciferase activities were determined 
after intraperitoneal injection of the substrate, luciferin, using a charged-coupled device 
(CCD) camera that allows monitoring gene expression in living animals (Fig. 4). Until day 
15, luciferase activities recorded after injection of either plasmids were similar, indicating that 
pFAR1 or the newly synthesised vector pFAR4 do not exert adverse effects after muscle 
transfection. At later time points, however, luciferase activities started decreasing in some 
mice. When sera were collected by retro orbital puncture, they appeared to contain antibodies 
directed against the exogenous luciferase protein. In the mouse showing a great decrease in 
luciferase activity, the amount of anti-LUC antibodies was of 14.5 μg/ml 30 days after 
plasmid injection, and reached 70 μg/ml at day 60.  
To assess luciferase expression in another tissue, pVAX2-LUC and pFAR4-CMV LUC BGH 
were then injected into mouse skin and electrotransferred. Figure 5 shows that luciferase 
activities in pVAX2.LUC-transfected cells decreased within a few weeks time. In marked 
contrast, the injection of the pFAR derivative led to sustained luciferase expression levels. In 
another experiment, a prolonged expression in skin cells was observed for more than three 
months (data not shown).  
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Discussion 
Production of recombinant therapeutic proteins or of plasmids most often implies growing 
bacteria in the presence of antibiotics to ascertain vector maintenance and propagation in 
prokaryotic cells. To avoid the risk of dissemination of antibiotic resistance markers to 
mammalian-colonizing endogenous flora and/or putative anaphylactic chocks due to the 
presence of these compounds in plasmid preparations, we developed a new system to produce 
plasmids Free of Antibiotic Resistance genes referred as pFARs. The strategy is based on the 
suppression of a nonsense amber mutation introduced into the essential E. coli thyA gene by a 
plasmid encoding a suppressor t-RNA.  
Nonsense mutations are of three types: amber, ochre or opal, resulting in UAG, UAA or UGA 
chain-terminating codons, respectively. We chose to introduce an amber nonsense codon into 
the thyA gene for two main reasons: (i) several studies have shown that amber mutations can 
be efficiently suppressed26,27,31 and (ii) the distribution of translation termination codons is as 
follows: 7.6% for UAG, 63% for UAA and 29.4% for UGA.32 Thus, the introduction of UAG 
suppressor t-RNA into E. coli was expected to have a moderate impact on host metabolism. 
This is also supported by the fact that most laboratory strains and a significant number 
(~30%) of wild-type E. coli isolates naturally contain amber suppressor t-RNA genes, with no 
apparent selective disadvantage.33,34 Furthermore, all amber mutations are not suppressed with 
an equal efficiency. Several factors seem to play a role, such as the nucleotides surrounding 
the nonsense codon being suppressed26 as well as the selected suppressor t-RNA.26,27,31 
Taking into account all of these parameters and work reported by Michiaels et al35 on the 
insertion of nonsense codon in the thymidylate synthase coding region, we chose to introduce 
the amber mutation in the thyA nucleotide sequence encoding histidine 147, which lies in the 
substrates binding pocket of the enzyme.35 This mutation resulted in thymidine auxotrophy 
that could be efficiently suppressed upon introduction of pFAR4.  
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pFAR4 is a new plasmidic DNA vector that was entirely synthesised. It carries an allelic form 
of hisR, the expression of which is under the control of prokaryotic regulatory elements, and 
encoding a histidine suppressor t-RNA that allows the insertion of the expected amino acid 
with a high efficiency (up to 100%).26,35 Indeed, the introduction of pFAR plasmids into the 
optimized thyA mutant allowed the selection of plasmid-containing bacteria, restoration of a 
normal growth to thymidine auxotrophic strains and high yield production of monomeric 
supercoiled expression vectors, as required for clinical trials.  
To assess the efficiency of pFAR plasmids as both non-viral gene vehicles and in vivo 
eukaryotic expression vectors, a luciferase-encoding pFAR derivative was injected and 
electrotransferred into mouse muscle and skin. Luciferase activities measured in pFAR 
derivatives- or pVAX2.LUC-transfected muscles were similar until the production of 
antibodies directed against the exogenous firefly luciferase protein. The specific humoral 
immune response against the reporter protein and probable cytotoxicity against luciferase-
expressing muscular fibres may account for the decrease in enzymatic activity. Similar 
observations have already been reported after injection and electrotransfer of other non-viral 
vectors.36 
Sustained luciferase expression observed in pFAR derivative-transfected skin cells was 
somehow unexpected as, it had, to our knowledge, never been observed before.37 There exist 
a few differences between pVAX2-LUC and pFAR4-CMV-LUC-Bgh: (i) pVAX2-LUC is 
~0.9-kb bigger (Fig. 3) and (ii) it contains 12 additional CpG motifs that are potential 
inflammatory hexanucleotides made of CG flanked by two purines and two pyrimidines.38,39 
Furthermore, whereas pVAX2-LUC harbours one GACGTT motif (Fig. 3), which was 
reported to have the most immunostimulatory effect in mice,39,40 the pFAR4 derivative carries 
none. Co-injection of pFAR4 with an immunostimulant CpG oligonucleotide (ODN 1668)39,40 
did not influence temporal luciferase gene expression in skin (our unpublished data). Further 
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analyse will be performed to determine the factors playing a role in the sustained gene 
expression level as well as the type of transfected skin cells. Anyhow, this interesting property 
of pFAR vectors may allow using skin cells to secrete therapeutic proteins at several defined 
sites but at a low dose, which might be beneficial for some applications. For high expression 
levels, skeletal muscle might be a better target as it represents a long life span organ with a 
large volume of accessible tissue capable of producing local and systemic factors.41 
Thus, pFAR plasmids appear to be efficient eukaryotic expression vectors suitable for the 
delivery of therapeutic genes and the treatment of a large range of human diseases. Our next 
objective is to assess this feasibility.  
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Materials and methods 
Microbiological and Molecular Biology manipulations 
Escherichia coli strains were grown in either complex (Luria-Bertani42 or Mueller Hinton43 
(Sigma-Aldrich, Lyon, France)) or minimal (M9)42 media supplemented with either 
antibiotics42 or thymidine (30 μg/ml). The DH5α strain44 was used for routine cloning 
procedures that were carried out as described in Sambrook et al.42 
E. coli mutants were isolated from strain MG1655 obtained from “The Coli Genetic Stock 
Center” (USA) (http://cgsc.biology.yale.edu) since, unlike most laboratory strains, it does 
contain suppressor t-RNA alleles (Accession number #U00096).32 
 
Construction of E. coli mutants 
E. coli mutants were isolated essentially as described by Posfai et al.45 using pST76-C to 
introduce mutated genes into the bacterial genome, and pST76-AsceP to select those strains in 
which the second event of recombination had occurred. Both plasmids have a thermosensitive 
origin of replication and are therefore easily cured from bacteria by growing them at 43°C in 
the absence of antibiotics.  
To construct the thyA mutant, a 2-kb region covering the thyA gene was amplified by PCR 
using the ExTaq polymerase (Takara, Lonza, Verviers, Belgium), MG1655 genomic DNA 
and primers (ThyA-F: CATGCGGTATTGCGCAGGC and ThyA-R: 
CGCTGTATCTGTTCCGTGTCT). The primers were designed to place the amber mutation 
in the centre of the 2-kb fragment. The PCR product was ligated to the cloning vector PCR2.1 
(Invitrogen, Illkirch, France) and sequenced. An amber mutation (His 147: CAT→TAG) was 
introduced into the thyA gene by site directed mutagenesis using the QuikChange® II Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) and ThyA-His147-F 
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(CGCTGGCACCGTGCTAGGCATTCTTCCAGTTC) and ThyA-His147-R 
(GAACTGGAAGAATGCCTAGCACGGTGCCAGCG) as primers. The mutated thyA region 
was then entirely sequenced to ascertain that the insert only contained the amber mutation. 
Plasmids PCR-thyA* and pST76-C were ligated after digestion by EcoRV and SmaI, 
respectively. Finally, the pUC replication origin from pCR2.1 was deleted by digesting the 
fusion plasmid by BamHI. The mutated thyA region was then introduced into the MG1655 
genome as described above, selecting for thymidine auxotrophic strains. Amplification by 
PCR of a 2.6-kb fragment covering the mutated region and sequence analysis confirmed that 
the mutated strain only contained an amber mutation in thyA and that the adjacent genes have 
not been affected by the crossing-over events.  
To construct the double thyA endA mutant, two 1-kb fragments, covering regions upstream 
(yggI) and downstream (rsmE) from endA, were amplified by PCR using MG1655 genomic 
DNA as a template, the ExTaq polymerase (Takara, Lonza, Verviers, Belgium) and two pairs 
of primers (GTCGGTTTTGCCATGAGTGC and 
tacccgggTAGACAAATAACGGTACATCAC) and 
(ttcccgggAGAGCTAACCTACACTAGCG and CCACTCTTCGTAGTTCTGCT), 
respectively. The PCR fragments were entirely sequenced after cloning into PCR2.1 
(Invitrogen, Illkirch, France). The 1-kb SmaI-XbaI fragment from PCR2.1-yggI was ligated to 
PCR2.1-rsmE digested with SmaI-SpeI, to give PCR2.1 delta endA. This latter plasmid 
(digested with ApaI and Klenow-treated) was fused to pST76-C (digested with SmaI). A 
BamHI deletion gave a plasmid only carrying the thermosensitive replication origin. The 
deleted endA region was introduced into the thyA mutant genome as described above.  
To construct the triple thyA endA recA mutant, two 1-kb fragments located upstream (ygaD) 
and downstream (recX) from recA were amplified by PCR using the MG1655 genomic DNA 
as a template, the ExTaq polymerase (Takara, Lonza, Verviers, Belgium) and two pairs of 
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primers (GTAATGGCAAACGGTCAGGC and 
gatcccgggGTCGATAGCCATTTTTACTCC) and 
(catcccgggGAAGGCGTAGCAGAAACTAAC and GTCGCCGAAGCTGAAGTTG), 
respectively. ygaD and recX were fused using the same protocol as previously described. 
PCR2.1.delta.recA was ligated to pST76-C after digesting the plasmids with XbaI (Klenow-
treated) and SmaI, respectively. The deleted recA region was introduced into the thyA endA 
mutant as described above. 
 
Construction and preparation of pFAR plasmids  
Plasmids that are Free of Antibiotic Resistance markers are called pFARs. pFAR1 is a 
derivative of pVAX225 that was obtained by replacing the cytomegalovirus promoter of 
pVAX1 (Invitrogen, Illkirch, France) by that of pCMV-β (Clontech, Ozyme, Saint-Quentin-
en-Yvelines, France). The Histidine t-RNA suppressor gene was amplified from pGFIB-
1.His(AS)31 by PCR using primers (gtccatggCTGGCGCCGCTTCTTTGAGC and 
ccccatggACGACGGCCAGTGCCAAG). The PCR fragment was digested with NcoI and 
inserted into pVAX2 digested with BspHI. The digestion of the resulting plasmid by HindIII 
(Klenow-treated) and PvuII, followed by a self-ligation, allowed the deletion of the 
kanamycin resistance gene, to give pFAR1.  
To construct pFAR1-LUC, the 1.7-kb BamHI-XhoI fragment containing the firefly 
cytoplasmic luciferase-encoding gene was isolated from pVAX2-LUC25 and introduced into 
pFAR1 digested with the same enzymes. To optimise the expression vector, a new plasmid, 
called pFAR4, was entirely synthesised (Geneart, Regensburg, Germany). The ~1.7 kb MluI-
PvuII fragment containing the expression cassette CMV-LUC-BGH cleaved from pVAX2-
LUC was introduced into pFAR4 digested with MluI and EcoRV, to give pFAR4-CMV LUC 
BGH. 
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For in vivo studies, plasmids were purified using Endofree preparation kits (Qiagen, Hilden, 
Germany). Endotoxin levels were determined by Lonza (Verviers, Belgium), using the LAL 
procedure. They were all below the detection limits (< 0.05 EU/ml). The quality of plasmids 
was assessed by calculating the ratio of light absorption (260 nm/280 nm) and by visualisation 
on Ethidium Bromide-stained 1% agarose gels. Light absorption at 260 nm was used to 
determine DNA concentration. 
 
in vivo studies 
6-8 weeks old female BALB/c mice (Charles River, L'Arbresle, France) and 6 weeks old 
female NMRI mice (Université catholique de Louvain, Brussels, Belgium) were used for 
plasmid intramuscular and intradermal injection, respectively. Prior to all procedures, the 
animals were anaesthetised by intraperitoneal injection of ketamine and xylazine as described 
by Bloquel et al.36 and Vandermeulen et al.20. Studies were conducted following the 
recommendations of the European Convention for the Protection of Vertebrates Animals used 
for Experimentation. All experimental protocols were approved by the Local Ethic 
Committees for animal care and use. 
Plasmids diluted in 30 μl of physiological serum were injected into BALB/c mouse tibial 
cranial muscles and electrotransferred, as described in Bloquel et al.,36 using two stainless 
steel plate electrodes placed on each side of the shaved leg and a G250 electropulsator 
(Sphergen, Evry, France) to deliver eight square-wave electric pulses (200 V/cm, 20 ms, 
2Hz). For intradermal electrotransfer, the abdomen skin was shaved 1 day prior to the 
experiments with a depilatory cream (Veet for sensitive skin, Belgium). Plasmid DNA (in a 
volume of 15 μl) was injected into the dermis at two-5 mm apart different sites, using a 
Hamilton syringe and a 30-gauge needle. Then, a cutaneous fold was performed and injection 
sites were placed between 2 mm spaced-plate electrodes (IGEA, Carpi, Italy).20 A short High 
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Voltage pulse (700 V/cm 100 µs) immediately followed by a Low Voltage pulse (200 V/cm 
400 ms) were applied approximately one minute after plasmid injection37, using a 
Cliniporator system (Cliniporator, IGEA, Carpi, Italy). For all experiments, conductive gel 
was used to ensure electrical contact with the skin (EKO-GEL, ultrasound transmission gel, 
Egna, Italy).  
Luciferase activities were recorded by using charged-coupled device (CCD) cameras that 
allow in vivo studies in living animals. Following intramuscular plasmid electrotransfer, 150 
μl of Luciferin (LUX Biotechnology, Edinburgh, UK) diluted in Phosphate Buffer pH 9.0 (2.5 
mg/ml), were injected intraperitoneally. Twenty minutes later, luciferase activities were 
recorded for two minutes using a Photon-Imager camera (Biospace, Paris, France). To 
measure luciferase activities in transfected skin, luciferin diluted in PBS without Mg2+ and 
Ca2+ (Xenogen corporation, Alameda, CA, USA) was injected intraperitoneally (i.p., 3 
mg/100 μl). Optical imaging was acquired using an IVIS50 system (Xenogen corporation, 
Alameda, CA, USA). The duration of luminescence acquisition was between 10 s and 60 s 
and was initiated 10 minutes after injection of the substrate. In both cases, luminescence 
levels were integrated in region of interest (ROI) drawn by hand around luminescence zones. 
Background luminescence was subtracted according to values obtained in ROI drawn on a 
non-transfected zone of the mice.36 
 
Titration of anti-LUC antibodies 
Antibodies against luciferase in mouse serum were titrated by ELISA, essentially as described 
by Bloquel et al,36 using luciferase (E1702, Promega, Madison WI, USA) to coat the 
microplates and a horseradish peroxidase-conjugated goat anti-mouse secondary antibody 
(NXA931, GE Healthcare, Uppsala, Sweden). To establish a standard curve, a serial dilution 
of a monoclonal antibody anti-luciferase (L2164, Sigma-Aldrich, Lyon, France) was used. 
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Titles and legends to figures 
 
Figure 1. Description of the strategy used to propagate pFAR plasmids. A nonsense 
mutation TAG was introduced into the E. coli thyA gene, resulting in thymidine auxotrophy. 
The mutant strain was isolated in the presence of thymidine that can penetrate into bacterial 
cells where it is transformed into dTMP, a precursor required for DNA polymerisation. In 
selective medium, only the strains containing a plasmid encoding a suppressor t-RNA i.e. 
inserting an amino acid in response to UAG can grow.  
 
Figure 2: Properties of pFAR plasmids. Fig. 2a. Topology of pFAR plasmids prepared 
from the thyA mutants. Native plasmid DNA (pFAR4-CMV LUC BGH: 3.7 kb) was loaded 
onto a 1.0% agarose gel and stained with ethidium bromide after electrophoresis. The pFAR 
derivative produced from the single thyA mutant (S) formed multimers (1x: mono, 2x: di…) 
whereas plasmids prepared from the triple thyA recA endA mutant (T) were mainly present as 
monomeric (noted 1x) closed circular DNA. Plasmid multimerisation was determined by 
comparison with the following markers: Sc: Supercoiled DNA ladder (Invitrogen, Illkirch, 
France ; bands correspond to supercoiled DNA with the following size: 2, 3, 4, 5, 6, 7, 8, 10, 
12, 14 and 16 kb) and L: Smart Ladder (Eurogentec, Seraing, Belgium ; bands correspond to 
linearised DNA fragments of 0.6, 0.8, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 10 kb). Fig. 2b. 
Introduction of pFAR plasmids into the optimised thyA mutant restored bacterial 
growth. Overnight cultures grown in MH broth were used to inoculate fresh medium to an 
initial optical density of OD600: 0.015. Cultures were incubated at 37°C under constant 
agitation and absorbance was measured every 20 minutes. The introduction of pFAR 
derivatives into the thyA endA recA mutant restored normal growth to the thymidine 
auxotroph strain, leading to high-density cultures (squares). For comparison, a growth curve 
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obtained with the strain DH5α-pVAX2-LUC propagated in MH supplemented with 
kanamycin is also indicated (circles). Data points are the means of duplicate experiments. Fig. 
2c. Production of pFAR plasmids. pFAR derivatives prepared from the optimised thyA 
mutant grown in MH medium are produced with a yield similar to that of pVAX2-LUC 
propagated in DH5α cultivated in LB medium supplemented with kanamycin. Both plasmids 
were prepared from strains having a similar OD600 (~ 0.9) using plasmid Nucleospin® 
columns (Macherey Nagel, Hoerd, France). Ten μl of undigested eluted DNA were loaded 
onto a 1% agarose gel, which was stained with ethidium bromide. 
 
Figure 3. Maps and plasmid sizes of pVAX2-LUC and pFAR derivatives. pFAR4 is a new 
and small plasmid vector. It has a size of 1.1-kb, it contains an origin of replication of pUC-
type, a histidine suppressor t-RNA gene expressed from prokaryotic regulatory elements and 
a multiple cloning site (MCS) to facilitate cloning procedures. The luciferase-expressing 
pFAR4 derivative is ~0.9 kb smaller than pVAX2-LUC, has a reduced CpG content and lacks 
the motif GACGTT (*) thought to mediate inflammatory responses in mice39,40. 
 
Figure 4. Luciferase activities in mouse tibial cranial muscles. 5 μg of pVAX2-LUC and 
an equimolar amount of luciferase expression cassette harboured by pFAR1-LUC and 
pFAR4-CMV LUC BGH diluted in 30 μl of physiological serum were injected into each 
tibial cranial muscle of 4 Balbc mice and subsequently electrotransferred. 3, 8, 15, 30 and 60 
days later, luciferin was injected intraperitoneally and luciferase activities were recorded in 
living animals using a CDD camera. Bars represent the mean values (± SEM). Crosses 
indicate individual values measured in each muscle. A dramatic decrease in luciferase activity 
(arrows) was observed in both muscles of a mouse, which appeared to produce high levels of 
anti-luciferase antibodies.  
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Figure 5. Luciferase expression after intradermal injection and electrotransfer of 
pVAX2-LUC and pFAR4 – CMV LUC BGH. 50 μg of pVAX2-LUC and an equimolar 
amount of luciferase expression cassette carried by pFAR4 CMV LUC BGH were injected 
and electrotransferred into the skin of 7 or 8 mice. Luciferin was injected intraperitoneally, 1, 
3, 6, 9, 14 or 21 days later and luciferase activities were monitored using a CDD camera.  
Bars represent the mean values (± SEM).  
 
 





